RSS | Login | Register

CHANTIX

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare CHANTIX to:

Generic Name for CHANTIX

Varenicline (as tartrate) 0.5mg, 1mg; tabs.

Legal Classification:

Pharmacological Class for CHANTIX

α₄β₂ nicotinic acetylcholine receptor partial agonist.

Manufacturer of CHANTIX

Pfizer Labs

Indications for CHANTIX

Smoking cessation aid.

Adult dose for CHANTIX

Provide patients with counseling and educational support. Set a target "quit date". Begin therapy 1 week before target quit date. Take after eating with a glass of water. ≥18yrs: initially 0.5mg once daily for 3 days, then 0.5mg twice daily for 4 days, then 1mg twice daily. May reduce dose if intolerable nausea or other adverse effects occur. Treat for 12 weeks; may continue 12 more weeks if patient successfully stops smoking to further increase the likelihood of abstinence. Severe renal impairment: initially 0.5mg once daily; may titrate to max 0.5mg twice daily. End stage renal disease with hemodialysis: max 0.5mg once daily if tolerated. Reevaluate if abstinence is not achieved after 1^st 12 weeks.

Children's dosing for CHANTIX

<18yrs: not recommended.

Warnings/Precautions for CHANTIX

Psychiatric disorders (monitor). Renal impairment. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for CHANTIX

Smoking cessation may affect metabolism of other drugs (eg, warfarin, theophylline, insulin). Increased adverse effects with nicotine replacement therapy.

Adverse Reactions for CHANTIX

Nausea, other GI effects (eg, constipation, flatulence, vomiting), sleep disturbance (eg, abnormal dreams, insomnia), headache; nicotine withdrawal symptoms (due to smoking cessation); serious neuropsychiatric symptoms (eg, behavioral changes, agitation, depression, suicidal ideation).

How is CHANTIX supplied?

Tabs—56
Starting Month PAK (0.5mg x 11 tabs + 1mg x 42 tabs)—1
Continuing Month PAK (1mg x 56 tabs)—1

Related Disease:

Smoking

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Marketing approval filed with FDA for Ariva-BDL as first modified risk tobacco product

February 22, 2010

Star Scientific announced that it has filed an application with the FDA for approval to market Ariva-BDL as a "modified risk" tobacco product under the Family Smoking Prevention and Tobacco Control Act of 2009.

FDA warns against use of electronic cigarettes

July 23, 2009

The FDA has notified healthcare professionals and patients that a laboratory analysis of electronic cigarette cartridge samples has found that they contain carcinogens (eg, nitrosamines) and diethylene glycol, a toxic chemical found in antifreeze.

Generic fruit and cinnamon flavored nicotine gum approved

July 08, 2009

The FDA has approved Watson's over-the-counter nicotine polacrilex gum in coated fruit and cinnamon flavors, the generic equivalent of GlaxoSmithKline Consumer Healthcare's smoking cessation aid, Nicorette Fruit Chill and Cinnamon Surge Coated gums.

Additional warnings for varenicline and bupropion

July 01, 2009

The FDA has notified healthcare professionals and patients that it has required manufacturers of varenicline (Chantix, from Pfizer) and bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban, from GlaxoSmithKline) to add new Boxed Warnings to the product labeling and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms.